




October 2025

New Study Enrolling

Boehringer Ingelheim THULITE

THULITE is a Phase 2 study assessing the efficacy of an oral pill for diabetic macular edema (DME). The goal of the study is to determine whether the medication improves vision in patients with DME.

Study Spotlight



Genentech GR44251 "Galette"

Austin Clinical Research is now participating in the Genentech GR44251 Galette study for patients with dry AMD with geographic atrophy (GA). Through a surgical procedure, new, healthy cells are transplanted to the area of the retina that is damaged from dry AMD. This therapy has the potential for vision restoration.



October 2025

Enrolling Trials

(Click on each study name for more info!)

Dry Age-Related Macular Degeneration (AMD)

[Regeneron R3918-AMD-2326 SIENNA](#)
[Boehringer Ingelheim 1484-0005 JADE](#)
[Genentech GR44251 GAlette](#)
[Roche BP45482](#)

Wet Age-Related Macular Degeneration (AMD)

[DFI17940 Sanofi](#)
[4DMT 4D-150-C003 4Front-1](#)
[Alcon RTE888-E001 Nova-1](#)

Diabetic Macular Edema (DME)

[Genentech BP44175 Pregonda](#)
[Genentech GR43828 THAMES](#)
[Boehringer-Ingelheim 1485-0018 Thulite](#)
[Eluminex EBS-105-02 LOTUS-2](#)

Diabetic Retinopathy

[Boehringer-Ingelheim 1436-0007 Crimson](#)

New Study Enrolling

DFI17940 Sanofi

A clinical trial for patients with Wet AMD (Age-Related Macular Degeneration). In this study, patients will receive a single dose of gene therapy which may reduce the need for frequent injections.